The MYGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MYGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MYGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MYGN Detailed Price Forecast - CNN Money||View MYGN Detailed Summary - Google Finance|
|View MYGN Detailed Summary - Yahoo! Finance||View MYGN Stock Research & Analysis - Zacks.com|
|View MYGN Trends & Analysis - Trade-Ideas||View MYGN Major Holders - Barrons|
|View MYGN Call Transcripts - NASDAQ||View MYGN Breaking News & Analysis - Seeking Alpha|
|View MYGN Annual Report - CompanySpotlight.com||View MYGN OTC Short Report - OTCShortReport.com|
|View MYGN Fundamentals - TradeKing||View MYGN SEC Filings - Bar Chart|
|View Historical Prices for MYGN - The WSJ||View Performance/Total Return for MYGN - Morningstar|
|View the Analyst Estimates for MYGN - MarketWatch||View the Earnings History for MYGN - CNBC|
|View the MYGN Earnings - StockMarketWatch||View MYGN Buy or Sell Recommendations - MacroAxis|
|View the MYGN Bullish Patterns - American Bulls||View MYGN Short Pain Metrics - ShortPainBot.com|
|View MYGN Stock Mentions - StockTwits||View MYGN Stock Mentions - PennyStockTweets|
|View MYGN Stock Mentions - Twitter||View MYGN Investment Forum News - Investor Hub|
|View MYGN Stock Mentions - Yahoo! Message Board||View MYGN Stock Mentions - Seeking Alpha|
|View Insider Transactions for MYGN - SECform4.com||View Insider Transactions for MYGN - Insider Cow|
|View MYGN Major Holdings Summary - CNBC||View Insider Disclosure for MYGN - OTC Markets|
|View Insider Transactions for MYGN - Yahoo! Finance||View Institutional Holdings for MYGN - NASDAQ|
|View MYGN Stock Insight & Charts - FinViz.com||View MYGN Investment Charts - StockCharts.com|
|View MYGN Stock Overview & Charts - BarChart||View MYGN User Generated Charts - Trading View|
New Studies Highlight Performance of Vectra® Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab
Posted on Friday October 19, 2018
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced new data from two studies of Vectra® that evaluated the test’s ability to track treatment response in patients with rheumatoid arthritis (RA). The studies were conducted by academic collaborators and will be presented at the American College of Rheumatology meeting in Chicago, IL. The key findings are that Vectra statistically significantly predicted response to tofacitinib and tracked response to rituximab.
See what the IHS Markit Score report has to say about Myriad Genetics Inc.
Posted on Thursday October 18, 2018
Myriad Genetics Inc NASDAQ/NGS:MYGN
Bendcare Endorses Vectra® Testing for Patients with Rheumatoid Arthritis
Posted on Thursday October 18, 2018
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, announced today that Bendcare, a large professional organization empowering community rheumatologists in the United States, has endorsed Vectra® testing for adults with rheumatoid arthritis (RA). Bendcare focuses on the optimization of the patient journey and the specialty medical office through provider and patient education, product acquisition, and world-class products and data solutions, including a revolutionary prospective data analytics platform called Columbus.
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Pfizer’s TALZENNA® (talazoparib)
Posted on Tuesday October 16, 2018
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer (mBC) who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, TALZENNA® (talazoparib). TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline (inherited) BRCA-mutated HER2-negative locally advanced or mBC. One in eight women are diagnosed with breast cancer in the United States, and one-third will progress to the metastatic stage of the disease.